The following interactive multimedia activities are available for this therapeutic area:
- High-Risk ACS: Overcoming the Limitations of Current Anticoagulant Therapy—Dialogue with the Experts
A Learner Interactive Case-Based CME Activity
Presenters: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI, Professor Philippe Gabriel Steg
In acute coronary syndrome (ACS) patients, including those at high risk, antithrombotic therapy is key in the prevention of primary and recurrent atherothrombotic events, and also in the prevention of ischemic complications. In fact, the development of antiplatelet and antithrombotic medications and invasive vascular procedures have decreased the rates of mortality and subsequent cardiac events in ACS patients; yet patients experience recurrent clinical thrombotic events at a rate approaching 10% in the following year.
Utilizing an audience interactive format, this case-based activity will provide an opportunity for expert faculty dialogue/commentary, and will address the clinical implications of current guidelines for use of anticoagulant therapy in ACS patients, the role of thrombin in normal hemostasis and pathologic thrombosis, the relationship between bleeding and outcomes in ACS, and efficacy and safety data from recent and ongoing trials of novel anticoagulant therapies being studied in ACS patients.
- CaseBook Challenges: Individualizing Antiplatelet Therapy in the Emergency Department—Dialogue with the Experts
A Learner Interactive Case-Based CME Activity
Presenters: Marc Cohen, MD, FACC, James Hoekstra, MD, FACEP, Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA
After initial evaluation and risk stratification, depending on diagnosis, patients who suffer ACS may be treated medically, by percutaneous coronary intervention (PCI), or surgically. The availability of novel antiplatelet therapies requires that ED clinicians be familiar with comparative safety and efficacy data, revisions to pertinent guidelines, and the potential role of the new therapies.
Utilizing an audience interactive format, this case-based activity provides an opportunity for expert faculty dialogue/commentary, and addresses the clinical implications of current guidelines for use of antiplatelet therapy in ACS patients, platelet function testing and/or genotyping, risk stratification tools, novel antiplatelet therapies, and strategies that balance efficacy and bleeding risk in relation to decision making in the emergency department.
- Mechanisms and Consequences of Cardiac Ischemia/Reperfusion Injury: Insights and Evidence to Improve Outcomes – A Case-Based Interactive Symposium
Presenters: Roberta A. Gottlieb, MD, Robert M. Mentzer, Jr., MD, and Frank W. Sellke, MD
Inadequate myocardial protection and ischemia/reperfusion injury are major problems associated with CABG surgery, making the need for cardioprotection necessary and urgent. This program provides clinicians with an understanding of the magnitude of ischemia/reperfusion injury and its consequences, the newest information on the various pathways and mechanisms of ischemia/reperfusion injury, and an overview of the recent research into cardioprotective options.
- The Foundation Role of Beta Blockers Across the Cardiovascular Disease Spectrum: A Year 2009 Update – An Interactive CME Program
Presenters: Henry R. Black, MD, Barry H. Greenberg, MD, and Michael A. Weber, MD
This program evaluates the evidence and defines the role of the newer vasodilatory, cardioselective beta blockers while examining the implication of their use to improve outcomes.
- Antiplatelet Therapy in ACS and PCI: Practical Strategies to Improve Outcomes – A Case-Based Interactive Symposium
Presenters: Dominick J. Angiolillo, MD, PhD, FACC, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, Gilles Montalescot, MD, PhD, and Stephen D. Wiviott, MD, FACC
Antiplatelet therapy in acute coronary syndrome (ACS) is evolving and recommended practice guidelines are changing. As data emerges, clinicians must evaluate new compounds in the context of risk stratification and individual patient profiles. This program reviews recent clinical information on both new and existing therapies.
- Antiplatelet Therapy in ACS: Applying New Science to Clinical Decisions –
A Case-Based Interactive Symposium
Presenters: Richard C. Becker, MD, C. Michael Gibson, MS, MD, FACC, Lisa K. Jennings, PhD, FAHA, FESC, and David A. Morrow, MD, MPH
This interactive, case-based activity reviews new knowledge of platelet physiology and risk stratification, and examines the latest clinical evidence for available and emerging antiplatelet therapies to improve the management and treatment of ACS.
- Lipid Profiling and Beyond: Significance of Advances in Cardiovascular Risk Assessment – A Case-Based Interactive Symposium
Presenters: Christie M. Ballantyne, MD, Michael H. Davidson, MD, FACC, and Jorge Plutzky, MD, FACC
Using patient cases and interactive discussion, this activity provides an update on the role of inflammation in atherosclerosis and heart disease, management of lipid profiles and markers of inflammation/cardiovascular risk, and the latest clinical evidence in the treatment of atherosclerosis and heart disease.